Resources - MECHANISMS
Mounjaro (tirzepatide) side effects: what the licence lists, what the trials found, and when they tend to happen
Every Mounjaro side effect on the UK licence, how common each one was in the trials, why most happen during dose increases, the serious ones to know about (pancreatitis, gallbladder, low blood sugar, severe dehydration), the hair-loss question, how it compares with Ozempic and Wegovy, and when to speak to a prescriber.
Mounjaro, the brand of tirzepatide licensed in the UK for type 2 diabetes and weight management, causes side effects in most people who take it, and for most of them the effects are stomach and gut symptoms that arrive with each dose increase and fade as the body adjusts. That is the honest summary of the trial data and the licence. This article goes through the full list the UK product information carries, how common each effect was in the clinical trials, when in treatment they tend to appear, the serious but uncommon ones that matter, the questions people search most, including hair loss and the contraceptive pill, how tirzepatide compares with semaglutide on tolerability, and when a symptom should send someone to a prescriber rather than a forum. It is written to explain the licensed medicine. It is not a recommendation to take it or to stop it; those decisions belong with the prescriber.
Where this information comes from
Two sources carry weight here. The first is the clinical trial programme, principally SURMOUNT-1, which followed 2,539 adults without diabetes for 72 weeks and recorded every adverse event, and the SURPASS trials in type 2 diabetes. The second is the UK product information, the Summary of Product Characteristics and the patient leaflet, which the MHRA approved on the basis of those trials and which is updated as post-marketing reports accumulate. The NHS medicines page summarises the leaflet in plain language. Forum accounts describe individual experiences, which are real but cannot say how common anything is. The frequencies below are trial frequencies for the licensed product at licensed doses; they do not describe unlicensed products sold online, whose contents and doses are unknown.
The common side effects and how often they occurred
The licence uses standard frequency bands: very common means more than one in ten people, common means between one in a hundred and one in ten, uncommon between one in a thousand and one in a hundred, and rare less than one in a thousand. In the weight-management trials the very common effects were nausea, diarrhoea, vomiting and constipation. Nausea affected roughly a quarter to a third of people on tirzepatide across the dose range, diarrhoea around a fifth, vomiting and constipation around one in ten, against much lower rates on placebo.
- Very common (more than 1 in 10): nausea, diarrhoea, vomiting, constipation, and in the weight-management trials abdominal pain. In people also taking a sulfonylurea or insulin, low blood sugar is also very common.
- Common (1 in 100 to 1 in 10): decreased appetite, indigestion, abdominal pain (very common in the weight-management trials), bloating, belching, wind, acid reflux, tiredness, dizziness, low blood pressure, injection-site reactions, hair loss, increased heart rate, gallstones, raised pancreatic enzymes on blood tests, and allergic reactions such as rash, itching or hives.
- Uncommon (1 in 1,000 to 1 in 100): acute pancreatitis, inflammation of the gallbladder, gallbladder-related complications, delayed stomach emptying, altered taste and unusual skin sensations.
- Rare (fewer than 1 in 1,000): severe allergic reactions including anaphylaxis and angioedema.
Two things about that list are worth pausing on. First, almost everything in the top two bands is gastrointestinal, which follows from how the drug works: it slows stomach emptying and acts on gut-hormone receptors, so the gut is where the effects are felt. Second, "common" covers a wide range; hair loss at around one in twenty and pancreatitis at less than one in a hundred are both real, but they are not the same kind of risk.
Why side effects cluster around dose increases
The licence starts tirzepatide at 2.5 mg weekly and increases it in 2.5 mg steps no faster than every four weeks, to a maintenance dose of 5, 10 or 15 mg. That schedule exists because of the side-effect pattern in the trials: gastrointestinal effects were most frequent in the first weeks and after each step up, and they were more frequent when escalation was faster. Most people found that a symptom appearing after a dose increase eased within days to a couple of weeks as they stayed on the new dose. This is why prescribers are permitted to delay an increase, hold at a lower dose, or step back down if a symptom is troublesome, and why "push through" advice from forums is the opposite of what the licence describes.
What to expect, roughly, over the first months
The trials did not report a week-by-week symptom diary, so the following is a synthesis of the frequency data and the escalation schedule rather than a timetable anyone should expect to follow exactly. In the first two to four weeks on 2.5 mg, reduced appetite and mild nausea are the most commonly reported effects; some people notice little. Each dose increase, which the licence spaces at least four weeks apart, tends to bring a few days of more noticeable nausea or altered bowel habit that settles. By the time a maintenance dose has been held for a month or two, most people report that gastrointestinal effects have become occasional rather than daily. A minority, more at higher doses, do not adapt, and the trials record them stopping treatment. Appetite reduction, which is the intended effect, persists throughout.
The serious side effects
Acute pancreatitis is the one the licence highlights most. It was uncommon in trials, but it is serious, and its warning sign is severe, persistent pain in the upper abdomen that may spread to the back, sometimes with vomiting. That symptom needs urgent medical attention and the medicine is stopped if pancreatitis is confirmed. Gallbladder problems, including gallstones and inflammation of the gallbladder, were more frequent on tirzepatide than placebo and are associated with rapid weight loss generally; pain under the right ribs, especially after eating, is the typical sign.
Severe gastrointestinal effects can lead to dehydration, and dehydration can injure the kidneys; the licence warns about this particularly in people with existing kidney disease. Low blood sugar is a risk mainly for people also taking insulin or a sulfonylurea, whose doses may need reducing when tirzepatide is started. Diabetic eye disease can worsen with rapid improvement in blood sugar, and people with existing retinopathy are monitored. Severe allergic reactions are rare but described. None of these is a reason to fear the medicine in the abstract; they are the reasons it is prescribed with a clinician attached.
Hair loss, the contraceptive pill, and the questions people actually search
Hair loss was reported by about one in twenty people on tirzepatide in the weight-management trials against about one in a hundred on placebo, enough for the licence to list it. It is generally attributed to rapid weight loss, which is a known trigger for temporary shedding a few months after the loss begins, rather than to a direct effect of the drug, and it usually recovers. Tirzepatide slows stomach emptying, which can reduce the absorption of oral medicines; the licence specifically advises women with obesity or overweight who use oral contraceptives to switch to a non-oral method, or add a barrier method, for four weeks after starting and for four weeks after each dose increase, because the pill may not be fully absorbed. Alcohol is not addressed by the licence; the NHS advises that it is best to avoid alcohol while using tirzepatide because it can increase nausea and vomiting. Injection-site reactions, redness or itching at the site, were common and mild; the licence recommends rotating sites.
Muscle, mood and the things the trials measured less well
Body-composition sub-studies found that lean mass fell as well as fat mass, as with any substantial weight loss, while the proportion of lean mass improved; whether that matters for strength or long-term health, and how much resistance exercise and protein intake offset it, is still being studied. Mood changes and suicidal thoughts were examined by regulators for the GLP-1 class in 2023 and 2024 after case reports; the reviews did not establish a causal link, and the medicines remain under routine monitoring. Altered taste is listed in the licence as uncommon. Vivid dreams and altered alcohol tolerance appear in post-marketing reports and on forums and are not established in trials. These are honest gaps, not hidden dangers, and they are the kind of thing a prescriber can put in context for a particular person.
Tirzepatide versus semaglutide on side effects
The two drugs share a side-effect profile because they share a mechanism. Across their separate trials, the rates of nausea, diarrhoea, vomiting and constipation are broadly similar at comparable stages of treatment, and discontinuation for adverse events sits in the same low single-digit percentage range. The SURMOUNT-5 head-to-head trial, which randomised adults with obesity to tirzepatide or semaglutide for 72 weeks, reported greater average weight loss on tirzepatide with a similar tolerability profile. The practical conclusion is that individual response varies far more than the two drugs do; someone who tolerates one badly may tolerate the other well, and that is a conversation for a prescriber.
Unlicensed products and why the frequencies above do not apply to them
Everything on this page describes pharmaceutical tirzepatide at licensed doses in monitored people. Products sold online as "research" tirzepatide, or as filled pens from unknown sources, are unlicensed: no regulator has checked what they contain, at what concentration, or whether they are sterile. Their side effects are unknowable in advance, because the dose is unknowable, and reports of harm from counterfeit and unlicensed weight-loss injections have been the subject of repeated MHRA warnings and seizures. If a side effect follows an unlicensed product, the relevant question is not "is this a Mounjaro side effect" but "what was in the vial", and medical help should be sought.
When to contact a prescriber, and how to report a side effect
- Severe or persistent abdominal pain, especially with vomiting: urgent medical attention, because of the pancreatitis and gallbladder risks.
- Signs of dehydration, such as very little urine, dizziness on standing or confusion, particularly with ongoing vomiting or diarrhoea.
- Symptoms of low blood sugar in anyone also taking insulin or a sulfonylurea.
- Any allergic reaction: swelling of the face or throat, difficulty breathing, widespread rash.
- Side effects that are not dangerous but are making treatment hard to continue: the prescriber can delay or reverse a dose step, which the licence allows for.
- Any suspected side effect can be reported to the MHRA through the Yellow Card scheme, which is how the safety profile of a medicine keeps being refined after licensing.
This article is educational content only and is not medical advice or a recommendation to start, stop or change any medicine. Mounjaro (tirzepatide) is a prescription-only medicine; the frequencies described are from clinical trials and the UK product information and are not predictions for any individual. Anyone experiencing side effects should speak to their prescriber or pharmacist, and seek urgent care for the serious symptoms described. Vivera Education sells nothing.
Frequently asked
- What are the most common Mounjaro side effects?
- Nausea, diarrhoea, vomiting and constipation are the most common, each affecting more than one in ten people in the trials at the higher doses, along with reduced appetite, indigestion, abdominal pain and tiredness. Most are mild to moderate and cluster around dose increases.
- How long do Mounjaro side effects last?
- In the trials, gastrointestinal effects were most frequent in the weeks after starting and after each dose increase, and lessened as people stayed on a dose. For most people they settle within days to a few weeks of each step; a minority found them persistent enough to stop.
- What are the serious side effects of Mounjaro?
- The licence lists acute pancreatitis, gallbladder disease including gallstones and inflammation, severe gastrointestinal effects leading to dehydration and kidney injury, low blood sugar when combined with insulin or a sulfonylurea, and rare severe allergic reactions. Severe or persistent abdominal pain needs urgent medical attention.
- Does Mounjaro cause hair loss?
- Hair loss was reported more often on tirzepatide than placebo in the weight-management trials, about one in twenty people versus one in a hundred, and is listed as a side effect. It is generally attributed to rapid weight loss rather than a direct drug effect and tends to be temporary.
- Does Mounjaro affect the contraceptive pill?
- Because tirzepatide slows stomach emptying, reduced effectiveness of oral contraceptives cannot be ruled out in women with obesity or overweight. The licence advises those women to switch to a non-oral method, or add a barrier method, for four weeks after starting and for four weeks after each dose increase; it says no adjustment is needed for women with a normal BMI.
- Is Mounjaro worse for side effects than Ozempic or Wegovy?
- The side-effect profile is the same family: gastrointestinal effects dominate for all three. Rates in trials are broadly similar at comparable stages; the SURMOUNT-5 head-to-head trial found similar tolerability with more weight loss on tirzepatide. Individual response varies more than the drugs do.
- How many people stop Mounjaro because of side effects?
- In SURMOUNT-1, between about 4% and 7% of people on tirzepatide stopped because of adverse events over 72 weeks, compared with about 3% on placebo, with more stopping at higher doses.
- What should I do if I get side effects?
- Speak to the prescriber or pharmacist, especially before deciding to stop or skip doses; they can delay a dose increase, adjust the dose or treat the symptom. Severe or persistent abdominal pain, signs of dehydration, or symptoms of low blood sugar need prompt medical attention. Suspected side effects can be reported through the MHRA Yellow Card scheme.
- What should you not take with Mounjaro?
- The licence does not prohibit any specific medicine, but it flags several groups. Insulin and sulfonylureas raise the risk of low blood sugar, so a prescriber may lower their dose. For women with obesity or overweight who use oral contraceptives, reduced effectiveness cannot be ruled out, so the licence advises switching to a non-oral method, or adding a barrier method, for four weeks after starting and for four weeks after each dose increase. For oral medicines where small changes in blood level matter, such as warfarin or digoxin, the licence recommends monitoring, especially when starting and after dose increases, because tirzepatide slows stomach emptying; the same slowing can delay oral medicines that need to work quickly. A prescriber or pharmacist should see the full medicines list.
- When is the best time of day to take Mounjaro?
- The UK product information says it is taken once a week, at any time of day, with or without meals; the patient leaflet adds that it should be used on the same day each week if possible. The trials did not compare times of day, so there is no evidence that one is better than another.
- Are there foods to avoid on Mounjaro?
- The licence lists no prohibited foods, and no individual food such as bananas is restricted. The NHS advises that it is best to avoid alcohol because it can increase nausea and vomiting. Beyond that, what people eat is a matter for the diet advice that accompanies the prescription.
- What is the black box warning on Mounjaro?
- A "black box" or boxed warning is a term from United States drug labelling. The US label for tirzepatide carries a boxed warning about thyroid C-cell tumours, based on findings in rats; whether the finding applies to humans is not known, and the US label rules the medicine out for people with a personal or family history of medullary thyroid cancer or MEN 2. The UK product information carries no boxed warning and no equivalent restriction; it reports the rat findings in its preclinical safety section and states that their relevance to humans is unknown.
The studies and sources behind this page
Lessons on this topic
Related reading
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.